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We investigated the clinical usefulness of oral supplementation with a combination product containing alpha-lipoic acid, curcumin
phytosome, andB-group vitamins in 180 patientswith carpal tunnel syndrome (CTS), scheduled to undergo surgical decompression
of themedian nerve. Patients in GroupA (𝑛 = 60) served as controls and did not receive any treatment either before or after surgery.
Patients inGroupB (𝑛 = 60) received oral supplementation twice a day for 3months both before and after surgery (totaling 6months
of supplementation). Patients in Group C (𝑛 = 60) received oral supplementation twice a day for 3 months before surgery only.
Patients in Group B showed significantly lower nocturnal symptoms scores compared with Group A subjects at both 40 days and
3 months after surgery (both P values < 0.05). Moreover, patients in Group B had a significantly lower number of positive Phalen’s
tests at 3 months compared with the other study groups (𝑃 < 0.05). We conclude that oral supplementation with alpha-lipoic acid,
curcumin phytosome, and B-group vitamins twice a day both before and after surgery is safe and effective in CTS patients scheduled
to undergo surgical decompression of the median nerve.
1. Introduction
Peripheral nerve compression syndromes (also known as
tunnel syndromes or entrapment neuropathies) are common
disabling conditions that occur when nerves are compressed
through bony, fibrous, osteofibrous, and fibromuscular tun-
nels, impairing nerve function [1]. The economic and social
costs of peripheral nerve compression syndromes are high
due to lost working days, change of occupation, and the
need for surgical intervention [2]. From a clinical standpoint,
patients with carpal tunnel syndromes can present with
motor, sensory, or autonomic findings, although they most
show motor and sensory complaints [1, 2].
Carpal tunnel syndrome (CTS) is the most common
entrapment neuropathy in the upper extremity, with a life-
time risk of approximately 10% [3]. CTS is caused by the
compression of the median nerve, which temporarily causes
conduction blockswithin largemyelinated nerve fibers, along
with the blockage of capillary blood flow to the median nerve
through the swelling of the ensheathing synovial tissue of
the tendons. The primary symptoms of classic CTS involve
numbness and tingling with or without pain in at least two of
the median nerve innervated fingers [3]. Symptoms are often
aggravated during sleep and in daytime caused by static or
repetitive hand function.The vastmajority of cases of CTS are
either idiopathic or spontaneous, presenting bilateral symp-
toms in over 60% of the patients [4]. Common conditions
related to secondary CTS include high energy wrist traumas,
endocrine disorders (e.g., diabetes mellitus and hypothy-
roidism), pregnancy, rheumatoid arthritis, anomalous carpal
tunnel structures, and occupational factors such as repetitive
motion or exposure to vibrating tools [5]. Patients with CTS
may experience quite variable sensory symptoms and pain
[3–5]. Paresthesia and pain may extend proximal to the wrist
in nearly 40% of cases, whereas predominant involvement of
the dorsum of the hand has been reported to occur in 11% of
the cases [3].
The mainstay of definitive therapy for severe CTS is
surgery [6], either with or without conservative approaches
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[7] aimed at limiting ischemia-induced changes in the nerve
and reducing inflammation of the flexor tenosynovium.
However, most of the conventional agents currently used in
the management of CTS are designed to hit a single target
in the pathophysiology of nerve compression. Unfortunately,
the physiological and mechanistic deregulations responsible
for CTS initiation and perpetuation implicate a number of
mechanisms, so that it appears evident that multitargeted
approaches are required to overcome this disabling entrap-
ment neuropathy [6, 7].
Alpha-lipoic acid [8, 9], curcumin [10, 11], and B-group
vitamins [12–14] have been shown to exert significant anti-
inflammatory, antioxidant, and neuroprotective effects in the
peripheral nerves. Recently, a form of curcumin coated with
phospholipids (curcumin phytosome) has greatly improved
its oral bioavailability (∼29 times greater than that of tradi-
tional curcumin) [15].
In this report, we sought to analyze the clinical useful-
ness of oral supplementation with a combination product
(Axin C) containing such active compounds in a sample
of CTS patients who were scheduled to undergo surgical
decompression of the median nerve. The primary aim of
this study was to compare the magnitude of symptoms
reduction (hyperalgesia, paresthesia, nocturnal symptoms,
and limitations to everyday life) in CTS patients who received
oral supplementation both before and after surgery compared
with those who did not. Secondary endpoints were the num-
bers of positive and negative results in Tinel’s and Phalen’s
tests, compliance, and patients’ subjective satisfaction with
oral supplementation.
2. Methods
2.1. Participants. This research was designed as a prospective,
observational study of 180 consecutive CTS patients (44
males and 136 females, mean age: 57.9 ± 14.8 years) who were
scheduled to undergo surgical decompression of the median
nerve at the IRCCS MultiMedica (Sesto San Giovanni, Italy).
The enrollment period was 6 months, with a planned min-
imum follow-up period of 3 months. The inclusion criteria
were as follows: (1) a diagnosis of CTS based on nerve
conduction studies and electromyography; (2) positive results
in Tinel’s [16] and Phalen’s tests [17]; (3) scheduled surgery
to decompress the median nerve, and (4) at least 18 years of
age. Patients with a positive history of autoimmune diseases,
rheumatologic conditions, and previous traumas to the wrist
were excluded. All subjects were Caucasian of Italian descent.
The study protocol conformed to the tenets of theDeclaration
of Helsinki and was approved by the local ethics committee.
Before the study, each participant was informed about the
purpose of the study and signed informed consents were
obtained.
2.2. Materials. Test materials were supplied by Agave Farma-
ceutici srl (Prato, Italy). The oral supplement tested in this
study (Axin C) was in tablet form and contained alpha-lipoic
acid (300mg), curcumin phytosome (500mg), and B-group
vitamins (vitamin B1, 1.05mg; vitamin B2, 1.2mg; vitamin B5,
4.5mg; vitamin B6, 1.5mg).The concentrations of the actives
were based on previous studies.
2.3. Procedures. The study participants (𝑛 = 180) were ran-
domly divided into three study groups (𝑛 = 60 each). Patients
in Group A served as controls and did not receive any sup-
plementation either before or after surgery. Patients in Group
B received one tablet twice a day both before and after surgery,
for 3 months each (totaling 6 months of supplementation).
Patients in Group C received one tablet twice a day before
surgery only for a total of 3months. A total of four assessment
visits were performed as follows: 𝑇
0
, baseline visit three
months before surgery; 𝑇
1
, visit immediately before surgery;
𝑇
2
, follow-up visit at 40 days; and 𝑇
3
, follow-up visit at 3
months.
2.4. Surgery. All patients underwent an endoscopic carpal
tunnel release procedure under a same-day surgery regimen.
Local anesthesia (without epinephrine) was performed with
levobupivacaine 2% (5mL) under median and ulnar nerve
blocks at the wrist. A pneumatic tourniquet was positioned
over the arm. A single-portal endoscopic carpal tunnel
release system (Arthrex Inc., Naples, FL, USA) was used
for this study. A single short (1 cm) transverse incision was
performed at the level of the distal cutaneous crease on
the volar side of the wrist. The incision was situated 1 cm
proximal to the pisiform and 1 cm medially to the radial side
of the wrist. After opening the brachial fascia proximal to the
transverse carpal ligament and entering into the carpal tunnel
space with a dissector, the endoscope was introduced and the
white, transverse fibers of the ligamentwere visualized.Under
clear vision, the ligament was cut by a retrograde release
blade located at the extremity of the optic. A complete section
of the ligament was confirmed after the detection of a “U”
image in the monitor (Figure 1). Such an approach drastically
reduced the risk of incomplete dissection of the ligament.The
wound was closed with steri-strip and a compressive dressing
was applied around the wrist and removed seven to ten days
from surgery. All of the patients were encouraged to use their
operated hand immediately on the first day from surgery,
while avoiding wet and heavy burdens. Physiotherapy was
undertaken in all patients to restore hand strength and ability.
2.5. Study Endpoints. The primary endpoint of the study was
the magnitude of symptoms reduction (hyperalgesia, pares-
thesiae, nocturnal symptoms, and limitations to everyday
life) in the three study groups. Each endpoint was evaluated
at each visit on a 6-point Likert scale ranging from 0
(minimum) to 5 (maximum). Secondary endpoints were
the numbers of positive and negative results in Tinel’s and
Phalen’s tests, compliance, and patients’ subjective satisfac-
tion with the oral supplementation.
2.6. Statistical Analysis. Categorical variables were assessed
as counts and percent frequency and compared using the
chi-squared test. The data were checked for normality using
the Kolmogorov-Smirnov test for continuous variables. Nor-
mally distributed variables were compared across different
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Figure 1: Progressive retrograde ligament section (panels a and b).
time points (𝑇
0
,𝑇
1
,𝑇
2
, and𝑇
3
) using one-way analysis of vari-
ance (ANOVA) followed by post hoc Newman-Keuls tests.
Skewed variables were analyzed using the nonparametric
Kruskal-Wallis test followed by post hoc Tukey’s test. Analysis
of covariance (ANCOVA) was used to adjust for potential
confounders. All statistical analyses were performed using
the SPSS 17.0 package (SPSS Inc., Chicago, IL, USA). A two-
tailed 𝑃 value < 0.05 was considered statistically significant.
Owing to the exploratory nature of the study, Bonferroni’s
correction was not applied.
3. Results
3.1. General Characteristics at Baseline. The baseline charac-
teristics of the three study groups at 𝑇
0
are shown in
Table 1. The treatment groups were generally well matched.
Specifically, the three groups were similar in terms of age,
sex, hyperalgesia, paresthesia, and positive results in Tinel’s
and Phalen’s tests at baseline. However, nocturnal symptoms
and limitations to everyday life at 𝑇
0
were found to be
significantly higher in patients in Group B than in the other
study groups.The study sample at baselinemay be considered
representative of a CTS population in need for surgical
intervention.
3.2. Primary Endpoints. The efficacy data for the primary
study endpoints are shown in Table 2. The results indicated
that patients in Group B had significantly lower nocturnal
symptoms scores compared with Group A subjects at both
𝑇
2
and 𝑇
3
visits (both 𝑃 values < 0.05). Interestingly, this
effect was evident despite higher nocturnal symptoms scores
inGroup B patients at baseline (Figure 2,𝑃 < 0.05, ANCOVA
after adjustment for potential confounders). However, no
significant differences were found between Group A and
Group C.
3.3. Secondary Endpoints. Table 3 shows the numbers of pos-
itive results in Tinel’s and Phalen’s tests. The results indicated
that patients in Group B had a significantly lower number of
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Figure 2: Changes in nocturnal symptoms observed in Groups A
and B in the four study visits. The results indicated that patients
in Group B had significantly lower nocturnal symptoms scores
compared with Group A subjects at both 𝑇
2
and 𝑇
3
visits (both 𝑃
values< 0.05). Interestingly, this effectwas evident despite the higher
baseline (𝑇
0
) nocturnal symptoms scores in Group B patients.
positive Phalen’s tests at 𝑇
3
compared with Group A (𝑃 <
0.05). However, we found no significant differences between
Group A and Group C. The compliance (assessed at the 𝑇
3
visit) was 100% in 128 subjects (71.1%), 75% in 30 subjects
(16.7%), 50% in 14 subjects (7.8%), and 25% in 8 subjects
(4.4%). The overall satisfaction with oral supplementation
was rated as excellent in 61 subjects (33.9%), good in 84
subjects (46.7%), average in 34 subjects (18.9%), and poor in
1 subject (0.5%). The supplement was well tolerated with no
apparent adverse events.
4. Discussion
The results from the present study indicate that CTS patients
who received oral supplementation with alpha-lipoic acid,
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Table 1: Baseline characteristics of the three study groups at 𝑇
0
(three months before scheduled surgery).
Variable Group A (𝑛 = 60), notreatment
Group B (𝑛 = 60),
supplementation 3 months
before and 3 months after
surgery
Group C (𝑛 = 60),
supplementation 3 months
before surgery only
𝑃
Age, years 60.1 ± 12.6 58.7 ± 14.1 55.0 ± 17.2 0.14
Male sex, (𝑛) 12 (20%) 15 (25%) 17 (28.3%) 0.56
Hyperalgesia 2.57 ± 1.18 2.88 ± 1.41 2.58 ± 1.29 0.34
Paresthesia 3.12 ± 1.01 3.41 ± 1.30 3.12 ± 1.27 0.32
Nocturnal symptoms 3.52 ± 0.95 3.97 ± 0.95 3.55 ± 1.14 <0.05
Limitations to everyday life 2.17 ± 1.10 2.41 ± 1.22 1.72 ± 1.05 <0.01
Positive Tinel’s test, (𝑛) 60 (100%) 58 (96.6%) 57 (95%) 0.21
Positive Phalen’s test, (𝑛) 56 (93.3%) 51 (85%) 53 (88.3%) 0.34
Hyperalgesia, paresthesia, nocturnal symptoms, and limitations to everyday lifewere rated on a 6-point Likert scale ranging from0 (minimum) to 5 (maximum).
Data are expressed as counts and percentages or means and standard deviations, as appropriate. Statistically significant differences across the study groups are
marked in bold.
curcumin phytosome, and B-group vitamins twice a day
both before and after scheduled surgery, for 3 months each
(totaling 6 months of supplementation), had a reduced
burden of nocturnal symptoms (as assessed at 40 days post-
surgery) and were less likely to have positive Phalen’s test at 3
months after surgery.The treatment was associated with high
satisfaction levels and good compliance.
In comparisonwith subjects suffering from radiculopathy
(who generally show day-time pain with arm use), night pain
is a common complaint of CTS patients [18, 19]. Importantly,
the patient may be awakened with night-time pain, with
a history of shaking the hand or flicking the wrist in an
attempt to alleviate the discomfort [3]. There is also evidence
suggesting that CTS patients who wake up at night because
of pain are less likely to improve over time with treatment
[3–5]. As night-time symptoms may be a sign of more
severe cases of CTS, our data suggest that a combined
supplementation approach with alpha-lipoic acid, curcumin
phytosome, and B-group vitamins may have some value in
reducing postsurgical night discomfort in CTS patients who
underwent surgical decompression of the median nerve. It
is worth noting that the benefits of oral supplementation
were evident in patients who received the alpha-lipoic acid,
curcumin phytosome, and B-group vitamins for six months
despite having a higher baseline score of nocturnal pain
before surgery. These data indicate that the beneficial effects
on night-time pain observed in this study were not due
to chance. Moreover, the results remained statistically sig-
nificant even after adjustment for potential confounders in
ANCOVA. Phalen’s wrist flexion test is the most commonly
reported provocative test for CTS and is generally the most
widely accepted [17]. For this test, the patient allows thewrists
to fall into full flexion letting the fingers dangle downward. If
a tingling sensation in the distribution of the median nerve
starts in less than one minute, it is considered a positive
sign for the presence of CTS. The reduction rates of positive
Phalen’s test at 3 months after surgery were higher in subjects
who received the oral supplementation for six months.
These results demonstrate that the combination of alpha-
lipoic acid, curcumin phytosome and B-group vitamins may
be useful not only in reducing night discomfort but also
in producing superior clinical results if started 3 months
before decompression surgery and continued for 3 months
thereafter.
Previous studies have suggested that the neuroprotective
effects of alpha-lipoic acid may limit and correct the clinical
course of CTS. In a study of 112 subjects with moderately
severe CTS, Di Geronimo et al. [9] reported a significant
reduction in both symptoms scores and functional impair-
ment after a 90-day treatment with a fixed association of
alpha-lipoic acid and gamma-linolenic acid. In addition, sup-
plementation resulted in a statistically significant improve-
ment of electromyographic findings [9]. Several mechanisms
may account for the potential clinical usefulness of alpha-
lipoic acid in CTS, including its potent antioxidant activity
[20] and its capacity to decrease neuronal sensitivity to pain
by selectively inhibiting neuronal T-type calcium channels
[21]. Moreover, animal studies have shown that alpha-lipoic
acid may offer some protection against nerve ischemia and
lipid peroxidation [22], help correct deficits in nerve blood
flow [23], and improve distal sensory and motor nerve
conduction [24].
Curcumin, a major active polyphenolic compound of
turmeric (Curcuma longa), has been reported to have signif-
icant neuroprotective effects [25]. Curcumin not only acts
as an effective antinociceptive agent [26] but also shows
significant anti-inflammatory properties which include its
inhibitory effects on the production of several inflammatory
mediators (e.g., NF-𝜅B, IKK-𝛽, COX-2, iNOS, TNF-𝛼, and
IL-6) [27]. The neuroprotective effects of curcumin have
also been explained by possible protection effects against
oxidative stress and the induction of antioxidative enzymes
[25].
Although their effectiveness as amonotherapy is still con-
troversial, B-group vitamins are often used as a conservative
and adjunct therapy in the treatment of CTS. In a Cochrane
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Table 3: Results of Tinel’s and Phalen’s tests (secondary study endpoints) in the four study visits.
Group A Group B Group C
𝑇
0
𝑇
1
𝑇
2
𝑇
3
𝑇
0
𝑇
1
𝑇
2
𝑇
3
𝑇
0
𝑇
1
𝑇
2
𝑇
3
Positive
Tinel’s test,
(𝑛)
60
(100%)
60
(100%)
18
(30%)∗
10
(16.6%)∗
58
(96.6%)
57
(95%)
14
(23.3%)∗
8
(13.3%)∗ 57 (95%)
57
(95%)
15
(25%)∗
12
(20%)∗
Positive
Phalen’s test,
(𝑛)
56
(93.3%)
57
(95%)
16
(26.6%)∗
12
(20%)∗
51
(85%)
51
(85%)
12
(20%)∗
4
(6.6%)∗†
53
(88.3%)
55
(91.7%)
13
(21.7%)∗
8
(13.3%)∗
Data are expressed as counts and percentages. Statistically significant differences between Group A and Group B at the 𝑇3 visit are marked in bold.
∗
𝑃 < 0.001
versus baseline. †𝑃 < 0.05 versus Group A at 𝑇3.
review, Ang and coworkers [28] have critically analyzed the
available evidence concerning the potential usefulness of B-
group vitamins for treating peripheral neuropathies. The lit-
erature review concluded that there ismoderate evidence that
B-group vitamins at high doses may determine a significant
short-term reduction in pain, numbness, and paresthesia in
these clinical entities [28].
The results of our study indicate that the clinical benefits
of supplementation with alpha-lipoic acid, curcumin phyto-
some, and B-group vitamins were evident only in patients
who received the supplements twice a day both for 3 months
before and a further 3months after scheduled surgery (Group
B). In contrast, we did not observe significant improvements
in patients in Group C, who received oral supplementation
twice a day for a total of 3 months before surgery only.
These data indicate that maintaining supplementation after
surgery clearly results in better outcomes as opposed to
discontinuing treatment. We, thus, believe that the lack of
adequate supplementation of CTS patients after surgery may
lead to poor control of symptoms, lost productivity, reduced
quality of life, and an increased incidence of complications.
The management of CTS after surgery, thus, requires con-
tinued supplementation to improve the clinical outcomes.
We also hypothesize that prolonged supplementation may
improve symptoms by increasing blood supply to the nerve.
In this regard, the blood supply needs of peripheral nerves
are known to be related to their conducting function [29].
Notably, lipoic acid has been shown to increase the blood flow
to the peripheral nerves [30].
There are several limitations to this study which need to
be mentioned. First, this study was conducted in Caucasian
individuals, so results cannot be simply extrapolated to
populations with different ethnic backgrounds. Second, our
study should be considered as an exploratory analysis and
independent replication is needed to extend and confirm our
results. CTS patients should be treated on an individual basis
according to each patient’s disease characteristics, based on
clinical trial data and influenced by the personal experience
of the surgeon.Third, althoughwe showed that a combination
treatment is effective in reducing nocturnal pain associated
with CTS, our study did not compare the effect of the
combination product with that of each compound alone
(i.e., alpha-lipoic acid, curcumin phytosome, and B-group
vitamins alone).
These caveats notwithstanding, the results of the present
study suggest that CTS patients who receive oral supplemen-
tation with alpha-lipoic acid, curcumin phytosome, and B-
group vitamins twice a day, for 3months both before and after
surgery, have a reduced burden of nocturnal symptoms at 40
days after surgery and are less likely to have a positive Phalen’s
test at 3 months after surgery. The treatment was associated
with high satisfaction levels and good compliance, suggesting
the potential clinical usefulness of this supplementation
before and after surgery in CTS patients scheduled for the
surgical decompression of the median nerve.
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